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AMP-activated protein kinase (AMPK) is a heterotrimer of α-catalytic and β- and γ-regula-
tory subunits that acts to regulate cellular and whole-body nutrient metabolism. The key
role of AMPK in sensing energy status has led to signiﬁcant interest in AMPK as a thera-
peutic target for dysfunctional metabolism in type 2 diabetes, insulin resistance and
obesity. Despite the actions of AMPK in the liver and skeletal muscle being extensively
studied, the role of AMPK in adipose tissue and adipocytes remains less well charac-
terised. Small molecules that selectively inﬂuence AMPK heterotrimers containing spe-
ciﬁc AMPKβ subunit isoforms have been developed, including MT47-100, which
selectively inhibits complexes containing AMPKβ2. AMPKβ1 and AMPKβ2 are the princi-
pal AMPKβ subunit isoforms in rodent liver and skeletal muscle, respectively, yet the con-
tribution of speciﬁc AMPKβ isoforms to adipose tissue function, however, remains largely
unknown. This study therefore sought to determine the contribution of AMPKβ subunit
isoforms to adipocyte biology, focussing on adipogenesis. AMPKβ2 was the principal
AMPKβ isoform in 3T3-L1 adipocytes, isolated rodent adipocytes and human subcutane-
ous adipose tissue, as assessed by the contribution to total cellular AMPK activity.
Down-regulation of AMPKβ2 with siRNA inhibited lipid accumulation, cellular adiponectin
levels and adiponectin secretion during 3T3-L1 adipogenesis, whereas down-regulation
of AMPKβ1 had no effect. Incubation of 3T3-L1 cells with MT47-100 selectively inhibited
AMPK complexes containing AMPKβ2 whilst simultaneously inhibiting cellular lipid accu-
mulation as well as cellular levels and secretion of adiponectin. Taken together, these
data indicate that increased expression of AMPKβ2 is an important feature of efﬁcient
adipogenesis.
Introduction
AMP-activated protein kinase (AMPK) is the downstream component of a protein kinase cascade that
responds to increases in AMP (or ADP) relative to ATP, resulting from such stimuli as hypoxia, nutri-
ent deprivation and ischaemia. AMPK acts to stimulate ATP synthesis and attenuate ATP consump-
tion, thereby maintaining energy balance [1–4]. Mammalian AMPK is a heterotrimer of an α-catalytic
subunit and regulatory β- and γ-subunits, in which the binding of AMP to the γ-subunit allosterically
activates AMPK whilst also promoting activating phosphorylation of the α-subunit at Thr172 by liver
kinase B1 (LKB1), effects antagonised by ATP [1,2]. The β-subunit contains a C-terminal domain that
forms the core of the heterotrimeric complex, in addition to a carbohydrate-binding domain of poorly
deﬁned function [1,2]. There are two isoforms of the α- and β-subunits and three isoforms of the
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γ-subunit, which exhibit differential tissue expression [5,6]. Furthermore, a number of direct AMPK activators,
such as A769662 and compound 991, have been developed, which have been demonstrated to bind a site
between the β-subunit carbohydrate-binding domain and the α-subunit [7]. Compounds binding at this site
show marked selectivity for AMPK complexes containing β1 rather than β2 [8], such that pharmacological tar-
geting of speciﬁc tissues based on their AMPKβ isoform expression is feasible.
In addition to the important role that AMPK plays in maintaining cellular energy metabolism, it is clear that
AMPK also contributes to the coordination of nutrient metabolism in the whole organism, with activated
AMPK inhibiting multiple pathways including lipogenesis, cholesterol synthesis, protein translation, hepatic
gluconeogenesis whilst stimulating fatty acid oxidation, feeding and striated muscle glucose uptake. As a conse-
quence, AMPK activation has attracted interest as a potential therapeutic target for dysfunctional metabolism
in insulin resistance, type 2 diabetes and obesity [1–4]. Indeed, recent studies have reported that a systemic
pan-AMPK activator improves glucose homeostasis in preclinical models [9] and that an AMPK activator tar-
geting complexes containing AMPKβ1corrects non-alcoholic fatty liver disease (NAFLD) in primate preclinical
models [10]. Despite the well-characterised actions of AMPK in muscle and liver, the role of AMPK in adipose
tissue and adipocytes remains less well characterised. AMPK stimulation in response to activators or
physiological stimuli such as fasting, exercise and catecholamines is associated with reduced lipogenesis and
insulin-stimulated glucose uptake, increased fatty acid oxidation and mitochondrial biogenesis, anti-
inﬂammatory signalling and altered adipocytokine secretion in cultured or primary isolated adipocytes and
white adipose tissue (WAT) [3,4]. Although the precise role of AMPK remains uncertain, AMPK activation is
associated with altered adipose tissue lipolysis [3,4] and AMPK activation has an important role in generating
and maintaining brown adipose tissue (BAT). In support of an important role for AMPK in adipose tissue
metabolism, AMPK activity is reduced in WAT from obese and insulin-resistant rodents and humans [11–13].
A number of studies have demonstrated that incubation with AMPK activators inhibited differentiation of
3T3-L1 preadipocytes or human mesenchymal stem cells into adipocytes in vitro [14–20] an effect phenocopied
by overexpression of AMPKα or LKB1 [21,22]. In keeping with an anti-adipogenic action of AMPK,
down-regulation of AMPK with siRNA has been reported to increase lipid accumulation and markers of
adipogenesis in 3T3-L1 preadipocytes and human mesenchymal stem cells [23–27] and silencing of the activat-
ing AMPK Thr172 kinases LKB1 or Ca2+-calmodulin-dependent kinase kinase-2 (CaMKK2) also increases
adipogenesis of 3T3-L1 preadipocytes [22,28,29]. These data suggest AMPK activation contributes to
suppression of lipogenesis and adipogenesis, yet it remains unclear as to the precise role of AMPK subunit
isoforms in adipogenesis. In rodents, AMPKβ1 and AMPKβ2 are the predominant AMPKβ isoforms in liver
and muscle, respectively, yet the role of AMPKβ isoforms in adipose tissue remains poorly characterised [3–5].
This study therefore sought to determine the contribution of AMPKβ subunit isoforms to adipogenesis in
3T3-L1 adipocytes.
Materials and methods
Materials
DMEM, FCS, newborn calf serum (NCS), penicillin/streptomycin, trypsin and mouse anti-GAPDH (#AM4300)
antibodies were purchased from Invitrogen (Paisley, U.K.). Rabbit anti-ACC (acetyl-CoA carboxylase, #3676),
anti-phospho-ACC S79 (#3661), anti-AMPKα (#2532), anti-phospho-AMPKα T172 (#2535), anti-AMPKβ1
(#4182), anti-AMPKβ2 (#4148), anti-AMPKβ1/β2 (#4150), anti-C/EBPα (CCAAT-enhancer-binding protein-α,
#8178), anti-LKB1 (#3047), anti-perilipin-1 (#9349) and anti-PPARγ (peroxisome proliferator-activated
receptor-γ, #2443) antibodies were purchased from Cell Signaling Technology (New England Biolabs, Hitchin,
U.K.). Sheep anti-AMPKα1, anti-AMPKα2, anti-AMPKβ1 and anti-AMPKβ2 antibodies used for immunopre-
cipitation of AMPK complexes containing speciﬁc subunit isoforms (or immunoblotting in the case of
anti-AMPKα1 and anti-AMPKα2 antibodies) were a kind gift from Professor D.G. Hardie (University of
Dundee) and have been described previously [30–32]. Donkey Infrared dye-labelled secondary antibodies and
REVERT total protein stain were from LI-Cor Biosciences (Cambridge, U.K.). Rabbit anti-adiponectin antibody
was a kind gift from Professor G.W. Gould (University of Glasgow) and has been described previously [33].
Ponceau-S, oil red O and Mayers haematoxylin were purchased from Sigma–Aldrich Ltd (Gillingham, U.K.).
Type 1 collagenase was from Worthington Biochemical Corp. (Lakewood, NJ, U.S.A.). MT47-100 was synthe-
sised as described previously [34]. Lipofectamine 2000 and siRNA targeted to AMPKβ1 (#s72125, #s72126) or
AMPKβ2 (#s99128, #s99130) as well as scrambled siRNA were purchased from Fisher Scientiﬁc UK Ltd
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(Loughborough, U.K.). Mouse adiponectin Quantikine ELISA kits were purchased from R&D systems
(Minneapolis, MN, U.S.A.). All other reagents were from sources described previously[20,35].
Human adipose tissue
The human adipose tissue lysates were those previously described [35], prepared from gluteal adipose tissue
biopsies of men aged 50–70 years with type 2 diabetes (duration > 6 months) and had been stored at −80°C
prior to AMPK isoform assay analyses. The North Glasgow University Hospitals National Health Service Trust
Ethics Committee approved the study, and all individuals gave written informed consent.
Isolation of rodent adipocytes
All animals were housed in a 12-h light dark cycle with access to food and water ad libitum. All experimental
procedures were carried out in accordance with the United Kingdom Animal Procedures Act (1986) and with
the ‘Guide for the Care and Use of Laboratory Animals’ published by the US National Institutes of Health
(eighth edition) at the University of Glasgow. Mesenteric and epididymal adipose tissues were rapidly excised
from male 8–12-week-old sv129 mice or 200–250 g male Sprague–Dawley rats immediately after being killed
and placed in pre-warmed (37°C) collection buffer (128 mmol/l NaCl, 4.7 mmol/l KCl, 5 mmol/l NaH2PO4,
1.2 mmol/l MgSO4, 20 mmol/l HEPES-NaOH, 1.5 mmol/l CaCl2, 1% (w/v) BSA, 10 mmol/l adenosine,
3 mmol/l glucose). Adipose tissue depots were weighed and 4 vol. of collection buffer containing type 1 collage-
nase (2 g/l) added. The tissue was chopped with scissors and incubated in a shaking water bath at 37°C for
15 min. Adipocytes were sieved into a warmed collection vial and washed by ﬂoatation with collection buffer
(three times) and collection buffer without BSA (two times). Livers were excised from male 8–12-week-old
sv129 mice and snap-frozen in liquid N2. Livers were homogenised by 20 passes in a Dounce homogeniser in 4
vol. IP buffer [50 mmol/l Tris–HCl, pH 7.4 at 4°C, 150 mmol/l NaCl, 50 mmol/l NaF, 1 mmol/l Na4P2O7,
1 mmol/l EDTA, 1 mmol/l EGTA, 1% (v/v) Triton-X-100, 1% (v/v) glycerol, 1 mmol/l dithiothreitol, 1 mmol/l
Na3VO4, 0.1 mmol/l benzamidine, 0.1 mmol/l phenylmethylsulphonyl ﬂuoride, 5 mg/l soybean trypsin inhibi-
tor] and sequential polyethylene glycol (PEG) precipitation was used to prepare 2.5–6.25% PEG precipitates.
PEG precipitates were resuspended in IP buffer prior to AMPK assay.
3T3-L1 cell culture
3T3-L1 preadipocytes (from ATCC, mycoplasm-free) were cultured in DMEM supplemented with 10% (v/v)
NCS. Differentiation into adipocytes was initiated 2 days post-conﬂuence when the culture medium was
replaced with DMEM supplemented with 10% (v/v) FCS, 0.5 mmol/l 3-isobutyl-1-methylxanthine (IBMX),
0.25 mmol/l dexamethasone, 1 mg/l porcine insulin and 5 mmol/l troglitazone. After 3 days, the medium was
replaced with DMEM supplemented with 10% (v/v) FCS, 5 mmol/l troglitazone and 1 mg/l insulin. After a
further 3 days the medium was replaced with DMEM supplemented with 10% (v/v) FCS. Adipocytes were used
for experimentation 8–12 days post-induction of differentiation. In experiments investigating the effect of
AMPKβ isoform down-regulation or MT47-100 on adipogenesis, 3T3-L1 preadipocytes were differentiated to
adipocytes in the absence of troglitazone.
Preparation of 3T3-L1 cell lysates
3T3-L1 preadipocytes/adipocytes were incubated in serum-free DMEM for 2 h prior to lysis in lysis buffer
[50 mmol/l Tris–HCl, pH 7.4 at 4°C, 50 mmol/l NaF, 1 mmol/l Na4P2O7, 1 mmol/l EDTA, 1 mmol/l EGTA,
1% (v/v) Triton-X-100, 250 mmol/l mannitol, 1 mmol/l dithiothreitol, 1 mmol/l Na3VO4, 0.1 mmol/l benzami-
dine, 0.1 mmol/l phenylmethylsulphonyl ﬂuoride, 5 mg/l soybean trypsin inhibitor] on ice. For analysis of
PPARγ and C/EBPα levels, 3T3-L1 cells cultured in six-well plates were lysed directly in 100 ml sample buffer
(50 mmol/l Tris–HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 0.1% (w/v) bromophenol blue, 50 mmol/l
dithiothreitol).
Immunoprecipitation and assay of AMPK activity
AMPK-speciﬁc isoforms were immunoprecipitated from 3T3-L1 preadipocytes and adipocytes, isolated rodent
adipocytes, and human subcutaneous adipose tissue using sheep anti-AMPKα1, anti-AMPKα2 [30],
anti-AMPKβ1 [31] or anti-AMPKβ2 [32] antibodies. The immunoprecipitates were then assayed for AMPK
activity using the SAMS substrate peptide as described previously [20,35].
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SDS–PAGE and immunoblotting
Equal amounts of protein, as determined by Bradford assay, were resolved by SDS–PAGE, transferred to a
nitrocellulose membrane and subjected to immunoblotting with the antibodies indicated as described previ-
ously [20,35]. Transfer of proteins was assessed by staining of immunoblots with Ponceau stain (0.5% (w/v)
Ponceau-S, 1% (v/v) acetic acid). Immunolabelled proteins were visualised using infrared dye-labelled second-
ary antibodies and an Odyssey Sa infrared imaging system (Li-Cor Biosciences UK Ltd, Cambridge, U.K.).
Band density was analysed with Image J software.
siRNA-mediated knockdown of AMPKβ isoforms
3T3-L1 preadipocytes were seeded in 12-well plates at 6 × 104 cells/well in 800 ml of the culture medium and
were allowed to attach overnight. At 70% conﬂuence, the culture medium was replaced with 800 ml/well fresh
culture medium, and 200 ml/well Opti-MEM I reduced serum medium containing 2 ml Lipofectamine 2000
and 0.5 mmol/l siRNA (scrambled or targeted to AMPKβ1 or AMPKβ2). After 24 h, the medium was replaced
with normal culture medium, and cells incubated for a further 24 h prior to differentiation.
RNA extraction from 3T3-L1 adipocytes and gene expression analysis
RNA was extracted from 3T3-L1 cells 0, 3, and 8 days after the initiation of differentiation using an RNeasy kit
(Qiagen). Between 400 and 1000 ng of RNA was reverse-transcribed using a High Capacity cDNA Reverse
Transcription kit (Applied Biosystems). qPCR was performed with an Applied Biosystems ABI-PRISM 7900HT
Sequence Detection System. Gene expression was normalised to TATA-binding protein (Tbp) using Assays on
Demand and QPCR master mix (Applied Biosystems) as described previously [20]. The following TaqMan®
Gene Expression Assays (Applied Biosystems) were used: Tbp (Mm01277042_m1), Prkab1 (AMPKβ1,
Mm01201921_m1) and Prkab2 (AMPKβ2, Mm01257133_m1). Relative levels of mRNA were assessed using
the ΔΔCt method.
Oil red O staining of 3T3-L1 adipocytes
3T3-L1 preadipocytes cultured on glass coverslips were incubated in the presence or absence of MT47-100 or
siRNA and at various intervals from the initiation of differentiation, cells were ﬁxed with 10% (v/v) formalin
for 1 h. Coverslips were subsequently washed once in 60% (v/v) isopropanol and left to dry completely prior to
incubation in 5.142 mmol/l oil red O, 60% (v/v) isopropanol for 10 min. Coverslips were then washed four
times with distilled water, left to dry and submerged in Mayers haematoxylin (Sigma–Aldrich) for 4 min fol-
lowed by 3% (v/v) NH4OH for 10 s. Coverslips were mounted onto slides and images captured using
AxioVision microscope software (Zeiss, Germany), with the investigator blinded as to the experimental
conditions.
Adiponectin secretion ELISA
Conditioned medium during 3T3-L1 adipogenesis was collected and adiponectin content assayed using a
mouse adiponectin Quantikine ELISA kit according to the manufacturer’s recommended protocol.
Statistical analysis
Results are expressed as mean ± SEM. Statistically signiﬁcant differences were determined using a two-tailed
t-test or one- or two-way ANOVA where appropriate, with P < 0.05 as signiﬁcant using GraphPad Prism
software.
Results
To examine whether levels of AMPK isoforms were altered during adipogenesis of 3T3-L1 adipocytes, levels of
each AMPK subunit isoform were assessed by immunoblotting in 3T3-L1 preadipocytes and 12 days post-
differentiation into adipocytes. There was no change in the relative proportion of AMPKα subunits, as assessed
by the ratio of AMPKα1:AMPKα2 during adipogenesis (Figure 1a,b), nor was there any marked change in the
total levels of AMPKα, as assessed with an antibody recognising both AMPKα1 and AMPKα2 (Figure 1e). In
contrast, there was a marked 2-fold increase in the levels of AMPKβ2 relative to AMPKβ1 as 3T3-L1 preadipo-
cytes were differentiated into adipocytes, observed by 4 days post-differentiation assessed with AMPKβ isoform-
speciﬁc antibodies (Figure 1a,c,e,f ). The increase in the AMPKβ2:AMPKβ1 protein ratio was associated with a
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signiﬁcant increase in the levels of Prkab2 mRNA relative to Prkab1, yet levels of Prkab2 mRNA were ∼30-fold
lower in preadipocytes and ∼15-fold lower in adipocytes relative to Prkab1 (Figure 1d). Furthermore, the
increase in the relative ratio of Prkab2:Prkab1 was largely due to increased levels of Prkab2 when normalised to
Tbp (Supplementary Figure S1). Similarly, when using an antibody that recognises both AMPKβ isoforms,
AMPKβ2 immunoreactivity was 15% in preadipocytes and 32% in adipocytes relative to AMPKβ1 immunor-
eactivity (Figure 1e,g). Intriguingly, a small, but signiﬁcant reduction in levels of the AMPK kinase, LKB1, was
also observed relative to levels of AMPKα, during days 2–8 of 3T3-L1 adipogenesis (Figure 1e,h).
Figure 1. AMPKβ2 levels increase during 3T3-L1 cell adipogenesis.
(a–c) 3T3-L1 preadipocytes were differentiated into adipocytes over 12 days and lysates prepared. Representative immunoblots
are shown a) with the molecular masses (in kDa) indicated. Quantiﬁcation of (b) AMPKα1:AMPKα2 or (c) AMPKβ2:AMPKβ1,
assessed using individual isoform-speciﬁc antibodies. (d–h) 3T3-L1 preadipocytes were differentiated into adipocytes and (d)
RNA or (e–h) lysates prepared at the indicated times during adipogenesis. (d) mRNA levels were assessed by qPCR and data
shown represents Prkab2 (AMPKβ2) mRNA expression relative to Prkab1 (AMPKβ1). (e–h) Lysate proteins were resolved by
SDS–PAGE and immunoblotted with the antibodies indicated. (e) Representative immunoblots are shown with the molecular
masses (in kDa) indicated. Quantiﬁcation of AMPKβ2:AMPKβ1 assessed using (f ) individual isoform-speciﬁc antibodies or (g)
antibodies recognising both AMPKβ isoforms and (h) LKB1:AMPKα levels over the duration of adipogenesis. Data is
representative of three independent experiments, * P < 0.05, ** P < 0.01, *** P < 0.001 relative to preadipocyte levels (c)
two-tailed t-test, (d and f–h) one-way ANOVA.
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The speciﬁc total AMPK activity did not signiﬁcantly change as 3T3-L1 preadipocytes differentiated into adi-
pocytes (Supplementary Figure S2). Furthermore, levels of phosphorylation of the AMPK substrate, ACC rela-
tive to total ACC did not alter during adipogenesis, although levels of both phosphorylated and total ACC
immunoreactivity increased during adipogenesis relative to total cellular protein levels (Supplementary
Figure S2). Assays of AMPK complexes containing speciﬁc α- and β-subunit isoforms immunoprecipitated
from 3T3-L1 preadipocytes and adipocytes conﬁrmed that there was no change in AMPKα subunit isoforms as
3T3-L1 cells differentiated from preadipocytes to adipocytes, with complexes containing AMPKα1 representing
92 ± 4% and 83 ± 13% of the total immunoprecipitated AMPKα activity, respectively (Figure 2a). In agreement
with the immunoblotting data, there was a marked increase in the total cellular AMPK activity of complexes
containing AMPKβ2 during adipogenesis of 3T3-L1 adipocytes (Figure 2b), yet surprisingly complexes contain-
ing AMPKβ2 accounted for 45 ± 6% of the total immunoprecipitated AMPKβ activity in preadipocytes, increas-
ing to 83 ± 5% of the activity in 3T3-L1 adipocytes (Figure 2b). Complexes containing AMPKα1 and AMPKβ2
also accounted for the majority of total AMPKα or AMPKβ immunoprecipitated activity in isolated adipocytes
from two WAT depots (mesenteric and epididymal) obtained from both rats and mice (Figure 3a,b), indicating
that 3T3-L1 adipocytes phenocopy the AMPK subunit isoform distribution in primary adipocytes. To deter-
mine whether this distribution of isoforms was also the case in human adipose tissue, the contribution of com-
plexes containing particular AMPKβ and AMPKα isoforms to total AMPK activity was also assessed in human
SCAT lysates obtained previously with ethical approval [35]. Similar to 3T3-L1 adipocytes and isolated rodent
adipocytes, complexes containing AMPKα1 or AMPKβ2 accounted for 80 ± 4% and 79 ± 3% of total immuno-
precipitated AMPKα or AMPKβ activity, respectively, in human SCAT (Figure 3c). To ensure that the low
levels of activity associated with complexes containing AMPKα2 and AMPKβ1 were quantitative and not due
to inefﬁcient measurement of activity in immunoprecipitates, AMPK activity was measured in both immuno-
precipitates and immunodepleted samples from mouse liver, which has previously been reported to contain
high levels of AMPKβ1 and AMPKα2 [36]. AMPK activity in anti-AMPKα1 and anti-AMPKα2 immunopreci-
pitates accounted for 98% of total AMPK activity (40.8 and 57.7%, respectively), whereas AMPK activity in
anti-AMPKβ1 and anti-AMPKβ2 immunoprecipitates accounted for 70% of total AMPK activity (59.2 and
11.1%, respectively; Supplementary Table S1). Recovery of AMPK activity in immunoprecipitates and immuno-
depleted samples combined was 84–98% relative to the original liver lysate (Supplementary Table S1).
Furthermore, the combined activity immunoprecipitated from 3T3-L1 cells with anti-AMPKβ1 and
anti-AMPKβ2 antibodies was 74.5 ± 7.0% in preadipocytes or 104.7 ± 41.0% in adipocytes (mean ± SEM, n = 3
in each case) of the combined activity immunoprecipitated with anti-AMPKα1 and anti-AMPKα2 antibodies.
These data indicate that AMPK activity may be a partial, but not a substantive underestimate in AMPKβ1
immunoprecipitates of the actual activity.
As there was a clear change in the levels and activity of complexes containing AMPKβ isoforms during adi-
pogenesis of 3T3-L1 cells, the effect of down-regulation of either AMPKβ1 or AMPKβ2 isoform was assessed
on the differentiation of 3T3-L1 preadipocytes. Incubation with siRNA targeting AMPKβ1 successfully down-
regulated levels of AMPKβ1 by 70 ± 7% after 48 h (day 0) in 3T3-L1 preadipocytes without altering levels of
AMPKβ2 (Figure 4a and Supplementary Figure S3). Similarly, siRNA targeting AMPKβ2 successfully down-
regulated levels of AMPKβ2 by 52 ± 9% without altering levels of AMPKβ1 (Figure 4a and Supplementary
Figure S3). Down-regulation of AMPKβ1 or AMPKβ2 tended to reduce ACC phosphorylation when compared
with scrambled control siRNA, yet this did not achieve statistical signiﬁcance except with siRNA targeted to
AMPKβ1 at day 1 (Figure 4a and Supplementary Figure S3). Adiponectin, which maintains healthy adipose
tissue expansion and regulates whole-body insulin sensitivity [37], is expressed and secreted by mature adipo-
cytes. Adiponectin immunoreactivity was observed in scrambled siRNA-treated 3T3-L1 cells 6–8 days after the
addition of adipogenic stimuli (Figure 4a,b). Down-regulation of AMPKβ1 in preadipocytes had no effect on
cellular levels of adiponectin 6–8 days after stimulation of adipogenesis, yet down-regulation of AMPKβ2 mark-
edly reduced adiponectin levels 6–8 days post stimulation (Figure 4b). Furthermore, adiponectin levels in con-
ditioned medium taken from cells 8 days after stimulation of differentiation were markedly lower in medium
from 3T3-L1 cells originally incubated with AMPKβ2 siRNA, whereas AMPKβ1 siRNA had no effect
(Figure 4c). Similar to adiponectin, down-regulation of AMPKβ2, but not AMPKβ1 markedly reduced induc-
tion of the lipid droplet-associated protein, perilipin-1 in later stages of adipogenesis (Figure 4d). Furthermore,
in 3T3-L1 preadipocytes incubated for 48 h with siRNA targeted to AMPKβ2, there was markedly less oil red
O staining 8 days after the addition of adipogenic stimuli, whereas cells incubated with siRNA targeting
AMPKβ1 exhibited similar lipid accumulation over time as those incubated with scrambled siRNA (Figure 4e).
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It is worth noting that although cells were only incubated with siRNA for 48 h prior to stimulation of differen-
tiation with insulin, dexamethasone and IBMX, when the media was removed, down-regulation of AMPKβ1
and AMPKβ2 was observed for up to 4 days after stimulation of differentiation, 6 days after the initial incuba-
tion with siRNA (Figure 4a and Supplementary Figure S3).
To further conﬁrm the important role of AMPK complexes containing AMPKβ2 in lipid accumulation and
adiponectin secretion, we incubated 3T3-L1 preadipocytes with the dihydroxyquinoline MT47-100, which has
previously been demonstrated to selectively inhibit AMPKβ2-containing complexes [34]. Incubation of 3T3-L1
preadipocytes with 100 mmol/l MT47-100, a concentration previously demonstrated to inhibit complexes con-
taining AMPKβ2 in isolated hepatocytes [34], inhibited the activity of immunoprecipitated complexes contain-
ing AMPKβ2 47 ± 3%, without inﬂuencing the activity of immunoprecipitated AMPKβ1 complexes (Figure 5a).
Concentrations lower than 100 mmol/l had no effect on AMPK activity in complexes containing either isoform
(Figure 5a). Incubation with AICAR, which is phosphorylated to the AMP mimetic ZMP within cells, thereby
activating all AMPK complexes, markedly stimulated the activity of immunoprecipitated complexes containing
AMPKβ1 or AMPKβ2 in 3T3-L1 preadipocytes, yet the statistical signiﬁcance of this stimulation in complexes
containing AMPKβ2 was absent upon preincubation with MT47-100 (Figure 5b). MT47-100 had no signiﬁcant
effect on basal AMPKα T172 phosphorylation, yet impaired AICAR-stimulated AMPKα T172 phosphorylation
(Figure 5c,d). Intriguingly, despite this inhibition of AMPKα T172 phosphorylation, MT47-100 had no effect
on basal or AICAR-stimulated phosphorylation of the AMPK substrate ACC (Figure 5c,e). Furthermore, as
Figure 2. Isoform-speciﬁc AMPK activity in 3T3-L1 preadipocytes and adipocytes.
AMPK was immunoprecipitated in lysates (100 mg) from 3T3-L1 preadipocytes or adipocytes using (a) antibodies speciﬁc to
AMPKα1 or AMPKα2 or (b) antibodies speciﬁc to AMPKβ1 or AMPKβ2 and AMPK activity assayed. The values are expressed
as % total AMPK activity (AMPKα1 + AMPKα2 or AMPKβ1 + AMPKβ2, respectively). Results shown are from three (AMPKα
isoforms in preadipocytes), four (AMPKα isoforms in adipocytes), ﬁve (AMPKβ isoforms in preadipocytes) or six (AMPKβ
isoforms in adipocytes) independent experiments. *** P < 0.001 relative to % activity in preadipocytes (unpaired t-test).
Figure 3. Isoform-speciﬁc AMPK activity in rodent adipocytes and human subcutaneous adipose tissue.
AMPK was assayed in AMPK isoform-speciﬁc immunoprecipitates of lysates (100 mg) prepared from (a and b) rodent
adipocytes isolated from mesenteric or epididymal adipose tissue or (c) human subcutaneous adipose tissue. Results shown
are from ﬁve (mouse and rat epididymal adipocytes), four (mouse mesenteric adipose tissue), three (rat mesenteric adipocytes)
or 10 (human subcutaneous adipose tissue) individual rodents or volunteers.
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Figure 4. Down-regulation of AMPKβ2 suppresses adiponectin levels and lipid accumulation in 3T3-L1 adipocytes. Part 1 of 2
3T3-L1 preadipocytes were incubated with siRNA targeted to AMPKβ1, AMPKβ2 or scrambled siRNA for 48 h prior to differentiation into
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expected, MT47-100 had no effect on ACC phosphorylation stimulated by the AMPKβ1-selective activator
A769662 (Figure 5c,e).
As MT47-100 inhibited complexes containing AMPKβ2 in preadipocytes, the effect of MT47-100 on adipo-
genesis was examined. Differentiation of 3T3-L1 preadipocytes in the presence of MT47-100 abrogated induc-
tion of perilipin-1 and adiponectin protein levels by day 8 (Figure 6a–c), with concomitant inhibition of
adiponectin secretion into the cell medium (Figure 6d) and lipid accumulation (Figure 6e). MT47-100 had no
signiﬁcant effect on AMPKα or ACC phosphorylation on any day during adipogenesis except a marked inhib-
ition of ACC phosphorylation at day 8 (Figure 6a and Supplementary Figure S4). Furthermore, MT47-100 had
no effect on the change of expression of AMPKβ2:AMPKβ1 during adipogenesis (Figure 6a and
Supplementary Figure S4).
Adipogenesis in 3T3-L1 adipocytes involves conﬂuent preadipocytes re-entering the cell cycle and undergo-
ing several rounds of division called mitotic clonal expansion (MCE), during which there is induction of the
key adipogenic transcription factors PPARγ and C/EBPα [14], which subsequently lead to the expression of
lipogenic proteins and adiponectin. Differentiation of 3T3-L1 preadipocytes was associated with an approxi-
mate doubling of the cell number over the ﬁrst 2 days, an effect that was not signiﬁcantly altered by
co-incubation in the presence of 100 mmol/l MT47-100 (Figure 7a). Furthermore, co-incubation of 3T3-L1
cells with MT47-100 during differentiation in the absence of troglitazone reduced PPARγ levels after 3 days yet
had no effect on C/EBPα levels (Figure 7b–d). In cells differentiated in the presence of troglitazone,
co-incubation with MT47-100 reduced levels of both PPARγ and C/EBPα (Figure 7b–d).
Discussion
These data clearly demonstrate that AMPKα1β2 complexes are the principal isoforms at the level of total cellu-
lar activity in rodent adipocytes and human adipose tissue. Furthermore, this phenotype is conserved during
adipogenesis in 3T3-L1 cells, when there is a change in expression from complexes containing AMPKα1β1 to
those containing AMPKα1β2. Suppression of AMPKβ2 activity in 3T3-L1 preadipocytes by siRNA-mediated
down-regulation or with MT47-100 abrogates adipogenesis, suggesting that the switch from complexes contain-
ing AMPKβ1 to complexes containing AMPKβ2 is important for efﬁcient adipogenesis in 3T3-L1 adipocytes.
The demonstration that AMPKα1 is the principal catalytic subunit isoform in terms of total cellular AMPK
activity in 3T3-L1 adipocytes, isolated rodent adipocytes and human SCAT agrees with previous reports [38–
41]. Furthermore, AMPK complexes containing β2 account for the majority of total cellular AMPK activity in
mouse and rat adipocytes isolated from two separate WAT depots as well as human SCAT, phenocopying
3T3-L1 adipocytes and suggesting the switch from complexes containing AMPKβ1 to those containing
AMPKβ2 during adipogenesis in 3T3-L1 cells reﬂects normal physiology.
Prior to this study, little was known concerning the role of AMPKβ isoforms in adipocyte function or
adipose tissue physiology. This substantial contribution of AMPKβ2 to total AMPK levels in adipocytes is in
agreement with the observation that AMPK activity is reduced by only ∼30% in WAT of mice lacking
AMPKβ1 [42]. Surprisingly, however, the activity of AMPKα1 or AMPKα2 in WAT of mice lacking AMPKβ2
has been reported to be unchanged [43], suggesting adipocytes in those mice may exhibit compensatory
increases in AMPKβ1 levels. In contrast with the kinase assay data showing AMPK complexes containing β2
account for the majority of total cellular AMPK activity in adipocytes, there was 7-fold or 3-fold greater
AMPKβ1 immunoreactivity relative to AMPKβ2 in preadipocytes and adipocytes, respectively, when assessed
using an antibody that recognises both AMPKβ isoforms. Even accounting for the potential underestimation of
AMPK activity in AMPKβ1 immunoprecipitates, complexes containing AMPKβ2 will represent the major
Figure 4. Down-regulation of AMPKβ2 suppresses adiponectin levels and lipid accumulation in 3T3-L1 adipocytes. Part 2 of 2
adipocytes. (a, b and d) Lysates were prepared after the indicated durations after initiation of differentiation and resolved by SDS–PAGE and
immunoblotting with the indicated antibodies. (a) Representative immunoblots are shown, repeated on two to ﬁve further occasions. Densitometric
analysis of (b) adiponectin or (d) perilipin-1 levels (days 6 and 8), normalised to Ponceau staining. (c) Conditioned media was collected from 3T3-L1
adipocytes at day 8 post-differentiation and adiponectin measured by ELISA in three independent experiments. (e) Cells were ﬁxed and stained with
oil red O at the times indicated during differentiation. Representative images from three independent experiments are shown, scale bar represents
20 mm. * P < 0.05, ** P < 0.01, *** P < 0.001 relative to scrambled siRNA (one-way ANOVA).
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Figure 5. MT47-100 inhibits AMPK activity of complexes containing AMPKβ2 and suppresses AICAR-stimulated AMPKα
T172 phosphorylation in 3T3-L1 preadipocytes.
3T3-L1 preadipocytes were incubated in the presence or absence of the indicated concentrations of MT47-100 for (a) 1 h or
(b–e) 30 min prior to incubation in the presence or absence of AICAR (2 mmol/l) or A769662 (100 mmol/l) for 1 h and cell
lysates prepared. (a and b) AMPKβ1 or AMPKβ2 were immunoprecipitated from lysates and AMPK activity subsequently
assessed in immunoprecipitates. Data shown are from (a) ﬁve or (b) three independent experiments. (c–e) Lysate proteins were
resolved by SDS–PAGE and immunoblotted with the indicated antibodies. (c) Representative immunoblots are shown, repeated
on two further occasions. Densitometric analysis of (d) phospho-AMPKα or (e) phospho-ACC relative to AMPKα and ACC,
respectively. *P < 0.05 relative to absence of MT47-100, $P < 0.05, $$P < 0.01, $$$P < 0.001 relative to absence of AICAR or
A769662 (one-way ANOVA).
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activity in 3T3-L1 adipocytes, rodent adipocytes and human SCAT. This suggests either that the antibody that
recognises both AMPKβ isoforms does not exhibit equal afﬁnity for each isoform or that the speciﬁc activity of
complexes containing AMPKβ2 is far greater than those containing AMPKβ1. During the preparation of this
manuscript, it was reported that the levels of AMPKβ2 relative to AMPKβ1 do not change between 3T3-L1
Figure 6. MT47-100 suppresses adiponectin secretion and lipid accumulation during adipogenesis.
3T3-L1 preadipocytes were differentiated in the presence or absence of MT47-100 (100 mmol/l), with media changed on days 3
and 6, when MT47-100 was re-introduced to the culture medium. (a–c) Cell lysates were prepared at the times indicated and
proteins resolved by SDS–PAGE and immunoblotting with the antibodies indicated. (a) Representative immunoblots, repeated
with similar results on two further occasions are shown. Densitometric analysis of (b) perilipin-1 or (c) adiponectin levels relative
to REVERT total protein stain at 8 days post-differentiation from three independent experiments. (d) Conditioned media were
collected from 3T3-L1 adipocytes differentiated in the absence or presence of MT47-100 (100 mmol/l) for 8 days and
adiponectin measured by ELISA in three independent experiments. (e) Cells were ﬁxed and stained with oil red O at the times
indicated during differentiation. Representative images from three independent experiments are shown, scale bar represents
20 mm. ** P < 0.01, *** P < 0.001 relative to absence of MT47-100 (b) 2-way ANOVA (c and d) unpaired t-test.
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preadipocytes and 3T3-L1 adipocytes using the same antibody, although mouse and human adipocytes exhib-
ited substantial levels of AMPKβ2 immunoreactivity [41]. The reasons for this discrepancy are uncertain.
Furthermore, the reason for the increase in AMPKβ2:AMPKβ1 during adipogenesis is likely to reﬂect altered
transcription of Prkab2 and Prkab1, respectively, as there was a concomitant increase in Prkab2 mRNA during
adipogenesis. Intriguingly, Prkab1 mRNA was expressed at a substantially higher level than Prkab2 mRNA.
Adipogenesis in 3T3-L1 adipocytes involves MCE, during which PPARγ and C/EBPα are induced [14],
leading to the expression of lipogenic proteins and adiponectin. Numerous previous studies have reported that
AMPK activation inhibits differentiation of preadipocytes [14,16–21], whereas down-regulation of AMPK
increases the extent of adipogenesis in preadipocytes [23–27]. The mechanism by which AMPK activation inhi-
bits adipogenesis includes early suppression of MCE and expression of PPARγ and C/EBPα, whilst maintaining
levels of Pref-1 (preadipocyte factor 1), which is normally suppressed during early adipogenesis [14–
19,21,24,26,27]. The inhibition of PPARγ expression by AMPK activation has further been reported to be
mediated by stimulation of Wnt/β-catenin signalling [17,44].
In contrast with these studies, the current study suggests that expression of AMPKβ2 is required for efﬁcient
adipogenesis of 3T3-L1 adipocytes. Two independent lines of evidence support this. Firstly, down-regulation of
AMPKβ2, but not AMPKβ1 in 3T3-L1 preadipocytes markedly attenuated lipid accumulation as well as levels
and secretion of the marker of late adipogenesis, adiponectin. These data suggest that the increase in AMPKβ2
Figure 7. MT47-100 inhibits cellular PPARγ and C/EBPα levels during differentiation of 3T3-L1 cells.
(a) 3T3-L1 preadipocytes in six-well plates were differentiated in the presence of troglitazone (1 mmol/l) and the absence or
presence of MT47-100 (100 mmol/l), trypsinised and counted using a Nexcelom Cellometer Auto 1000 on the days indicated
after commencement of differentiation. Data shown represent the mean ± SEM cells/well from three independent experiments.
*** P < 0.001 relative to day 0 (two-way ANOVA). (b–d) 3T3-L1 preadipocytes were differentiated in the absence or presence of
MT47-100 (100 mmol/l) as well as troglitazone (1 mmol/l) and cell lysates were prepared 3 days post-differentiation and equal
volumes resolved by SDS–PAGE and immunoblotting with the antibodies indicated. (b) Representative immunoblots, repeated
with similar results on two further occasions are shown. (c and d) Densitometric analysis of protein levels relative to total lysate
protein, assessed with REVERT total protein stain (Li-Cor Biosciences). Data shown represents the mean ± SEM relative to
vehicle control. * P < 0.05, ** P < 0.01 relative to absence of MT47-100 (two-way ANOVA).
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levels is required for efﬁcient adipogenesis, yet the suppression of AMPKβ1 does not increase the adipogenic
potential of the preadiocytes, indicating that increased AMPKβ2 and not decreased AMPKβ1 underlies the
effect on adipogenesis. Secondly, MT47-100, which inhibited AMPKβ2-containing complexes without altering
the activity of AMPKβ1-containing complexes markedly inhibited both lipid accumulation and adiponectin
levels and secretion, phenocopying the effect of AMPKβ2-targeted siRNA. Interestingly, the switch from
AMPKβ1 to AMPKβ2 occurred early (days 2–4) during adipogenesis, suggesting an early effect regulated by
adipogenic transcription factors. Furthermore, inhibition of complexes containing AMPKβ2 with MT47-100
was associated with suppression of PPARγ and C/EBPα levels, without altering cell number during MCE, sug-
gesting that complexes containing AMPKβ2 contribute to increased adipogenic transcription factor expression
at this point.
These data are supported by previous studies using the poorly-selective AMPK inhibitor, compound C,
which has also been demonstrated to inhibit adipogenic gene expression, MCE and lipid accumulation during
adipogenesis in 3T3-L1 cells and CH3H10T1/2 mesenchymal stem cells [19,45,46], yet the AMPK-dependence
of this effect was not demonstrated in those studies and compound C has also been reported to increase adipo-
genic gene expression in human adipose tissue mesenchymal stem cells [24]. We and others have previously
reported that incubation of mouse embryonic ﬁbroblasts (MEFs) lacking AMPKα1 and AMPKα2 with adipo-
genic stimuli failed to increase lipid accumulation compared with wild type MEFs, further suggesting that some
AMPK activity is required for adipogenic gene expression [19,47], which has also been observed in MEFs
lacking LKB1 [47].
MT47-100 inhibited AMPKβ2 complexes without altering AMPKβ1 complex activity in unstimulated and
AICAR-stimulated 3T3-L1 preadipocytes, as assessed with assays of immunoprecipitated AMPK which reﬂect
activity due to covalent modiﬁcation of AMPK. Despite this, MT47-100 had no signiﬁcant effect on
phospho-AMPKα Thr172 levels in unstimulated 3T3-L1 preadipocytes, but did inhibit AICAR-stimulated
Thr172 phosphorylation. Furthermore, MT47-100 was only effective at a concentration that has previously
been demonstrated to inhibit AMPKβ2 complexes and allosterically stimulate AMPKβ1-containing complexes
in isolated mouse hepatocytes [34]. It remains entirely possible that either MT47-100 or siRNA targeted to
AMPKβ complexes have off-target effects that might inﬂuence adipogenesis, yet the marked correlation
between these two divergent but complimentary methods of down-regulating AMPKβ2 strongly argue against
this effect being independent of AMPKβ2.
We and others have reported that the AMPK activator, A769662, which selectively activates AMPK com-
plexes containing the β1 isoform [48], inhibits adipogenesis in 3T3-L1 cells and CH3H10T1/2 mesenchymal
stem cells [16,19,20], suggesting that AMPKβ1 activation suppresses adipogenesis. Although an
AMPKβ1-mediated effect of MT47-100 cannot be completely ruled out, down-regulation of AMPKβ1 using
siRNA had no effect on adipogenesis in 3T3-L1 cells, such that the effect of MT47-100 is far likelier to be
mediated by AMPKβ2 inhibition, as it phenocopies siRNA-mediated AMPKβ2 down-regulation.
Mice lacking AMPKα1 exhibit reduced adipose tissue mass and smaller adipocytes [40]. Similarly, mice with
a global deletion of AMPKβ1 exhibit reduced fat mass [42], yet no WAT phenotype has been reported in mice
that lack AMPKβ2 [43], although they have been reported to exhibit increased susceptibility to adiposity in
response to a high fat diet [49]. Whether impaired adipogenesis contributes to the adipose phenotypes of
AMPKα1 or AMPKβ1 knockout mice has not been assessed, as it is compromised by the multiple effects of
AMPK on carbohydrate and lipid metabolism, as well as feeding behaviour. More recently, mice with adipose-
targeted deletion of AMPK subunit isoforms have been developed [50–52], yet they have utilised the adiponec-
tin promoter to drive recombination in mature adipocytes, rather than preadipocytes, such that early adipogen-
esis would likely be unaffected by genetic alterations in those mice.
Taken together, the data presented in this study demonstrate a hitherto unappreciated role for AMPK com-
plexes containing AMPKβ2, to improve the efﬁciency of early adipogenesis of 3T3-L1 adipocytes. The mechan-
isms underlying this action of AMPKβ2 complexes containing AMPKβ2 remain uncertain, yet likely involve
improvements in PPARγ- and C/EBPα-mediated transcription after the MCE stage.
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